https://www.nejm.org/doi/full/10.1056/NEJMoa1601747
Betrixaban (Portola) is one example that I know of that missed the primary endpoint in cohort 1 (narrowly). The subsequent analyses were considered exploratory and were significant. The drug still was approved on the basis of this trial.